VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Machiels on Toxicities with Pembrolizumab for Head and Neck Cancer

Jean-Pascal Machiels, MD
Published: Monday, Jun 19, 2017



Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses toxicities with pembrolizumab (Keytruda) in combination with chemoradiation for patients with head and neck cancer.

The main adverse event to expect when treating a patient with pembrolizumab for head and neck cancer are endocrine side effects. However, it is also important to be aware of possible serious adverse events such as colitis or liver toxicities, states Machiels.
 


Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses toxicities with pembrolizumab (Keytruda) in combination with chemoradiation for patients with head and neck cancer.

The main adverse event to expect when treating a patient with pembrolizumab for head and neck cancer are endocrine side effects. However, it is also important to be aware of possible serious adverse events such as colitis or liver toxicities, states Machiels.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x